CN103751206A - Medicinal composition for preventing Alzheimer's disease and application thereof - Google Patents

Abstract

The invention belongs to the technical field of medicine, and specifically relates to a pharmaceutical composition for preventing Alzheimer's syndrome and its application. Astragalus polysaccharide fraction A1, astragalus polysaccharide fraction A2 and wolfberry polysaccharide fraction I have the advantages of obvious effect on preventing Alzheimer's syndrome, stable quality control, natural non-toxicity and suitable for long-term administration.

Description

Pharmaceutical composition for preventing Alzheimer's syndrome and its application

technical field

The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for preventing Alzheimer's syndrome and its application.

Background technique

Alzheimer's syndrome is a persistent high-level neurological activity disorder, that is, in the state of no disturbance of consciousness, obstacles in memory, thinking, analysis and judgment, visuospatial recognition, emotion, etc.

The main preventive principles include: ① Use brain metabolism activators (coenzyme Q10, citicoline) and brain circulation promoters (hydroergot alkaloids, flunarizine) to activate brain metabolism and indirectly inhibit the development of dementia. Cerebral metabolism activators mainly promote glucose absorption and metabolism, secondary expansion of cerebral blood vessels, and improve nutrient metabolism, while cerebral circulation enhancers are drugs that directly expand cerebral blood vessels; ② drugs for the treatment of neurotransmission block, such as amantadine Promote the release of dopamine and inhibit its reuptake; high calcium pantothenate can promote the absorption and metabolism of glucose in the brain, increase the concentration of serotonin in brain tissue and cerebral blood flow, and significantly improve neurological symptoms; prodrugs of acetylcholine (lecithin, chloride Choline) and cholinesterase inhibitors (physostigmine, tetrahydroaminopyridine) improve neurological symptoms by increasing the function of the acetylcholine system; neuropeptides can improve the cognition and memory of the elderly, and reduce depression and weakness symptoms;③ For symptomatic treatment, thioridazine, fluphenazine, fluperbutanol, etc. are often used to control the impatience and excessive behavior of patients with Alzheimer's syndrome; Ritalin and cloxacyl are commonly used to improve the depression symptoms of patients with Alzheimer's syndrome; Diazepam is commonly used to improve anxiety symptoms in patients with Alzheimer's syndrome.

Contents of the invention

The purpose of the present invention is to overcome the defects in the prior art, and provide a pharmaceutical composition for preventing Alzheimer's syndrome with stable quality control, safe and effective, natural and non-toxic, and suitable for long-term administration and its application.

The object of the present invention is achieved in this way: the pharmaceutical composition is prepared from the following raw materials: terpene-3β-alcohol, resveratrol, astragalus polysaccharide component A1, astragalus polysaccharide component A2 and wolfberry polysaccharide component I .

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials prepared in parts by weight: 5-100 parts of terpene-3β-alcohol, 5-100 parts of resveratrol, Astragalus polysaccharide component A110-100 parts, astragalus polysaccharide component A210-100 parts and wolfberry polysaccharide component I10-100 parts.

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials prepared in parts by weight: 5-80 parts of terpene-3β-ol, 5-80 parts of resveratrol, Astragalus polysaccharide component A110-100 parts, astragalus polysaccharide component A210-100 parts and wolfberry polysaccharide component I10-100 parts.

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials prepared in parts by weight: 5-50 parts of terpene-3β-alcohol, 5-50 parts of resveratrol, Astragalus polysaccharide component A110-50 parts, astragalus polysaccharide component A210-50 parts and wolfberry polysaccharide component I10-50 parts.

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials formulated in parts by weight: 5 parts of terpene-3β-ol, 5 parts of resveratrol, and components of astragalus polysaccharide A123 parts, astragalus polysaccharide component A217 parts and Lycium barbarum polysaccharide component I19 parts.

The present invention provides the application of the above pharmaceutical composition in the preparation of the pharmaceutical composition for preventing Alzheimer's syndrome.

The unkissed terpene-3β-ol, resveratrol, astragalus polysaccharide component A1, astragalus polysaccharide component A2, and Lycium barbarum polysaccharide component I described in the present invention can be directly obtained from the market, or can be obtained through plant extraction. In the present invention, the above raw materials are pulverized and sieved according to parts by weight, mixed, packed into capsules or pressed into tablets; or mixed with pharmaceutically acceptable carriers or diluents, then packed into capsules or pressed into tablets.

The present invention also provides the method of taking the pharmaceutical composition. The dosage is based on the composition: adults, 30-40 mg/time, 3 times/day; children, 15-20 mg/kg·time, 3 times/day day, it can achieve the effect of preventing clinical symptoms of Alzheimer's syndrome. It is pointed out that pregnant women and other special groups should follow the doctor's advice when taking it, and no special adverse reactions have been found so far. The "prevention" in the present invention means the intervention before the onset, not the treatment after the onset.

Untethered terpene-3β-alcohol in the present invention is extracted from leaves of Euonymus alatus (Thunb.) Sieb.] and Euonymus japonicUs Thunb.; The leaves and stems of japonicum Thunb.]; the stems and leaves of Euphorbia antiquorum L. and Bischofia polycarpa (Levl.) Airy Shaw. Molecular formula: C ₃₀ H ₅₂ O, molecular weight: 428.73.

Resveratrol, extracted from the fresh root of Polygonum cuspidatum Sieb.et Zucc. Molecular formula: C ₁₄ H ₁₂ O ₃ , molecular weight: 228.24.

Astragalus polysaccharide component A1 is extracted from the rhizome of Astragalus membranceus (Ficch.) Bunge.], a leguminous plant.

Astragalus polysaccharide component A2 is extracted from the rhizome of Astragalus membranceus (Ficch.) Bunge.], a leguminous plant.

Lycium barbarum polysaccharide component I, extracted from the fruits of Lycium barbarum [Lycium barbarum L] and Chinese wolfberry [Lycium chinense Mill.] of Solanaceae plants.

According to the research, the compound composed of terpene-3β-ol, resveratrol, astragalus polysaccharide fraction A1, astragalus polysaccharide fraction A2, and Lycium barbarum polysaccharide fraction I can effectively inhibit the morphological changes of rat nerve tissue and improve the The cognition, learning and memory ability of rats can significantly reduce the symptoms of Alzheimer's syndrome, and the preventive effect is better than that of ergometrine, citicoline, calcium hyperpantothenate, amantadine and lecithin.

Proved that the present invention can effectively improve the cognition, learning and memory abilities of rats through the rat platform test and rat dark avoidance test, and the preventive effect is better than that of ergonovine, citicoline, hyperpantothenate calcium, and adamantane amines and lecithin.

Observation by light microscope shows that the present invention can significantly inhibit the arrangement disorder of the three layers of pyramidal cells in the CA1 region of the rat hippocampus, the swelling of the pyramidal cells, the infiltration of inflammatory cells, the hyperplasia of astrocytes, and the small or triangular shape of some pyramidal cell bodies. , Prolonged apical dendrites, nuclear pyknosis and rupture, eosinophilic cytoplasm, loose matrix with microvacuole formation and erythrocyte exudation around blood vessels and other morphological changes.

Observation by electron microscope reveals that the present invention obviously inhibits morphological changes such as nuclear pyknosis, chromatin aggregation, heterochromatin increase, appearance of perinuclear high electron density clumps and fusion of mitochondrial cristae in rat hippocampal CA1 pyramidal cells.

The invention has the advantages of obvious effect on preventing Alzheimer's syndrome, stable quality control, natural and non-toxic and suitable for long-term administration.

Description of drawings

示意图。Fig. 1 is the impact of the present invention on the incubation period of rat platform jumping and dark avoidance test

schematic diagram.

示意图。Fig. 2 is the impact of the present invention on the number of mistakes in rat platform jumping and dark avoidance tests

schematic diagram.

Fig. 3 is a schematic diagram of the influence of the present invention on the morphology of cortical pyramidal cells in the CA1 region of the rat hippocampus (light microscope 0.8K×).

Fig. 4 is a schematic diagram of the influence of the present invention on the morphology of cortical pyramidal cells in the CA1 region of the rat hippocampus (electron microscope 12K×).

Detailed ways

The present invention is a pharmaceutical composition for preventing Alzheimer's syndrome and its application, and the present invention will be further described in conjunction with specific examples. The specific implementation is as follows:

Embodiment one

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials formulated in parts by weight: 5 parts of terpene-3β-ol, 5 parts of resveratrol, and components of astragalus polysaccharide A110 parts, astragalus polysaccharide component A210 parts and Lycium barbarum polysaccharide component I10 parts.

Embodiment two

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials prepared according to parts by weight: 27.5 parts of terpene-3β-ol, 27.5 parts of resveratrol, and astragalus polysaccharide components A130 parts, astragalus polysaccharide component A230 parts and Lycium barbarum polysaccharide component I30 parts.

Embodiment three

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials formulated in parts by weight: 42.5 parts of terpene-3β-ol, 42.5 parts of resveratrol, and astragalus polysaccharide components A142.5 parts, astragalus polysaccharide component A242.5 parts and wolfberry polysaccharide component I42.5 parts.

Embodiment Four

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials formulated in parts by weight: 50 parts of terpene-3β-ol, 50 parts of resveratrol, and astragalus polysaccharide components A150 parts, astragalus polysaccharide component A250 parts and wolfberry polysaccharide component I50 parts.

Embodiment five

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials prepared according to parts by weight: 52.5 parts of terpene-3β-ol, 52.5 parts of resveratrol, and components of astragalus polysaccharide A155 parts, Astragalus polysaccharide component A255 parts and Lycium barbarum polysaccharide component I55 parts.

Embodiment six

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials prepared according to parts by weight: 80 parts of terpene-3β-ol, 80 parts of resveratrol, and astragalus polysaccharide components A180 parts, astragalus polysaccharide component A280 parts and wolfberry polysaccharide component I80 parts.

Embodiment seven

A pharmaceutical composition for preventing Alzheimer's syndrome. The pharmaceutical composition comprises the following raw materials formulated in parts by weight: 100 parts of terpene-3β-ol, 100 parts of resveratrol, and astragalus polysaccharide components A1100 parts, astragalus polysaccharide component A2100 parts and wolfberry polysaccharide component I100 parts.

Embodiment Eight

A pharmaceutical composition for preventing Alzheimer's syndrome, the pharmaceutical composition comprises the following raw materials formulated in parts by weight: 5 parts of terpene-3β-ol, 5 parts of resveratrol, and components of astragalus polysaccharide A123 parts, astragalus polysaccharide component A217 parts and Lycium barbarum polysaccharide component I19 parts.

The above-mentioned embodiments are only examples for clearly illustrating the present invention, rather than limiting the implementation. For those skilled in the art, other changes or changes in different forms can be made on the basis of the above description. It is not necessary and impossible to exhaustively list all the implementation modes here, and the obvious changes or changes derived therefrom are still within the scope of protection of the claims of the present invention.

The present invention can be prepared into various forms of medicaments, such as: water solvent, powder and Mixture and other forms; when the water solvent needs to be prepared, the medicine is weighed according to the following weight: 50 mg of terpene-3β-ol, 50 mg of resveratrol, 1230 mg of astragalus polysaccharide component A, 170 mg of astragalus polysaccharide component A and 190 mg of wolfberry polysaccharide component I, Soluble in triple distilled water, then pack. When the powder needs to be prepared, the medicine is weighed according to the following weights: terpene-3β-alcohol 5g, resveratrol 5g, astragalus polysaccharide component A123g, astragalus polysaccharide component A217g and wolfberry polysaccharide component I19g, mixing, subpackaging Can. When the mixture needs to be prepared, the medicine is weighed according to the following weights: terpene-3β-alcohol 5g, resveratrol 5g, astragalus polysaccharide component A123g, astragalus polysaccharide component A217g and wolfberry polysaccharide component I19g, mixing, packaging, Filling capsules.

Experimental example 1

Detect the influence of the present invention on the platform jumping and dark avoidance tests of rats.

1. Raw materials: untethered terpene-3β-ol, resveratrol, astragalus polysaccharide component A1, astragalus polysaccharide component A2, wolfberry polysaccharide component I The above raw materials were all purchased by Shanghai Kexing Trading Co., Ltd.; hydrogenated ergot alkaloids were purchased by Shanghai Huatai Pharmaceutical Co., Ltd. purchased; citicoline was purchased by Suzhou Tianma Fine Chemicals Co., Ltd.; calcium hyperpantothenate was purchased by Shanghai Jialun Biotechnology Co., Ltd.; amantadine was purchased by Shijiazhuang Sanhe Pharmaceutical Co., Ltd. Purchased by the company; lecithin was purchased by Guangzhou Bangli Biotechnology Co., Ltd.

2. Instruments: The rat jumping platform recording system was purchased by Huaibei Zhenghua Biological Instrument Equipment Co., Ltd., and the rat dark avoidance instrument was purchased by Huaibei Zhenghua Biological Instrument Equipment Co., Ltd.

3. Animals: Sprague-Dawley (SD) rats, 6 weeks old, male, 180-220 g, clean grade provided by the Experimental Animal Center of Henan Province.

4. Experimental grouping: (1) Blank control group: 20 healthy SD rats, fed with triple distilled water on an empty stomach every morning, with a volume of 10ml/kg, for 8 consecutive weeks; (2) Alzheimer's syndrome (3) low-dose group of the present invention: 20 Alzheimer's syndrome model rats were gavaged with the solution of the present invention on an empty stomach every morning, with a gavage concentration of 10 mg/kg and a gavage capacity of 10 ml/kg kg administration, continuous gavage for 8 weeks; (4) middle dose of the present invention group: 20 Alzheimer's syndrome model rats, gavage with the solution of the present invention on an empty stomach every morning, gavage concentration 20mg/kg, gavage The capacity is 10ml/kg administration, and continuous gavage for 8 weeks; (5) high-dose group of the present invention: 20 Alzheimer's syndrome model rats are gavaged with the solution of the present invention on an empty stomach every morning, and the concentration of gavage is 30mg/kg. kg, with a gavage capacity of 10ml/kg, for 8 consecutive weeks; (6) Hydroergot alkaloid group: 20 Alzheimer's syndrome model rats were intragastrically administered with hydroergot alkaloid solution on an empty stomach every morning. The gastric concentration was 2.0mg/kg, and the intragastric volume was 10ml/kg, and the intragastric administration was continued for 8 weeks; (7) Citicoline group: 20 Alzheimer's syndrome model rats were fed with citicoline on an empty stomach every morning. Diphosphorylcholine solution was gavaged with a concentration of 1.0 mg/kg and a volume of 10 ml/kg for 8 weeks; (8) High calcium pantothenate group: 20 rats with Alzheimer's syndrome Gavage with high pantothenate calcium solution on an empty stomach every morning, with a concentration of 2 mg/kg and a volume of 10 ml/kg, for 8 consecutive weeks; (9) Amantadine group: Alzheimer's syndrome 20 model rats were fed with amantadine solution on an empty stomach every morning, with a concentration of 0.5 mg/kg and a volume of 10 ml/kg, for 8 consecutive weeks; (10) lecithin group: Alhai 20 Mursch syndrome model rats were gavaged with fasting lecithin solution every morning, with a concentration of 0.2 mg/kg and a volume of 10 ml/kg, for 8 consecutive weeks.

5. Experimental content: Rat jumping platform test, rat dark avoidance test.

表示。组间差异比较用ANOVA及Newman-Student多重比较；t检验分析，由SPSS13.0统计软件完成，双侧P＜0.05认为差异有显著性。6. Statistical method: All data are expressed as mean ± standard deviation

express. Differences between groups were compared using ANOVA and Newman-Student multiple comparisons; t test analysis was completed by SPSS13.0 statistical software, and bilateral P<0.05 was considered significant.

7. Results

7.1 The influence of the present invention on the rat platform test: the test results show that the present invention can obviously improve the incubation period of the rat platform test, reduce the number of mistakes, and has significant dose dependence; Calcium pantothenate, amantadine, lecithin control group, there is a significant difference (P <0.05). (See Table 1 for the results)

Table 1 The present invention is to the impact of rat platform test

Note: Compared with the Alzheimer's syndrome model group, *P<0.05; compared with the high-dose present invention group, #<0.05.

7.2 The influence of the present invention on the dark avoidance test of rats: test results show that the present invention can obviously improve the latent period of the dark avoidance test of Alzheimer's syndrome rats, reduce the number of mistakes, and have significant dose dependence; , citicoline, calcium pantothenate, amantadine, lecithin control group, there are significant differences (P <0.05). (See Table 2 for the results)

Table 2 The present invention is to the influence of dark avoidance test of Alzheimer's syndrome rat

Note: Compared with the Alzheimer's syndrome model group, *P<0.05; compared with the high-dose present invention group, #<0.05.

7.3 The influence of the present invention on the incubation period of rat platform jumping and dark avoidance test: test results show that the present invention can obviously improve the incubation period of Alzheimer's syndrome rat platform jumping and dark avoidance test, and has significant dose dependence; and hydrogenated ergot Alkaline, citicoline, calcium pantothenate, amantadine, lecithin control group, there is a significant difference (P <0.05).

As shown in Figure 1, Fig. 1 is the impact of the present invention on rat platform jumping, avoiding the dark test incubation period (Compared with the Alzheimer's syndrome model group, *P<0.05; compared with the high-dose present invention group, #<0.05). Test results show that the present invention can significantly improve the incubation period of rat platform jumping and dark avoidance tests, and has significant dose dependence; compared with hydrogenated ergot alkaloids, citicoline, hyperpantothenate calcium, amantadine, and lecithin control groups , there was a significant difference (P<0.05). The blank control group shown in Fig. 1 is 1; the Alzheimer's syndrome model group is 2; the low dose group of the present invention is 3; the middle dose group of the present invention is 4; the high dose group of the present invention is 5; 6 in the Citicoline group; 7 in the Citicoline group; 8 in the Pantocalcic acid group; 9 in the Amantadine group; 10 in the Lecithin group.

7.4 Influence of the present invention on the number of errors in rat platform jumping and dark avoidance tests: test results show that the present invention can significantly reduce the number of errors in Alzheimer's syndrome rat platform jumping and dark avoidance tests, and has significant dose dependence; Compared with the control group of hydrogenated ergot alkaloid, citicoline, calcium pantothenate, amantadine and lecithin, there was a significant difference (P<0.05).

(与阿尔海默式综合症模型组比较，*P＜0.05；与本发明组比较，#＜0.05)。试验结果显示，本发明可明显减少阿尔海默式综合症大鼠跳台、避暗试验错误次数，并且具有显著的剂量依赖性；与氢化麦角碱、胞二磷胆碱、高泛酸钙、金刚烷胺、卵磷脂对照组比较，有明显差异(P＜0.05)。图2中所示的空白对照组为1；阿尔海默式综合症模型组为2；低剂量本发明组为3；中剂量本发明组为4；高剂量本发明组为5；氢化麦角碱组为6；胞二磷胆碱组为7；高泛钙酸组为8；金刚烷胺组为9；卵磷脂组为10。As shown in Figure 2, Fig. 2 is the impact of the present invention on the number of mistakes in rat platform jumping and dark avoidance tests

(Compared with the Alzheimer's syndrome model group, *P<0.05; compared with the group of the present invention, #<0.05). The test results show that the present invention can significantly reduce the number of errors in the platform jumping and dark avoidance tests of Alzheimer's syndrome rats, and has a significant dose dependence; Compared with the amine and lecithin control groups, there was a significant difference (P<0.05). Blank control group shown in Fig. 2 is 1; Alzheimer's syndrome model group is 2; Low dose the present invention group is 3; Middle dose present invention group is 4; High dose present invention group is 5; 6 in the Citicoline group; 7 in the Citicoline group; 8 in the Pantocalcic acid group; 9 in the Amantadine group; 10 in the Lecithin group.

Experimental example 2

Detect the influence of the present invention on the morphology of pyramidal cells in the CAi region of rat hippocampus.

1. Raw materials: untethered terpene-3β-ol, resveratrol, astragalus polysaccharide fraction A1, astragalus polysaccharide fraction A2, wolfberry polysaccharide fraction I The above raw materials were all purchased by Shanghai Kexing Trading Co., Ltd.

2. Instruments: TS1000 Nikon microscope, HT7700 Hitachi transmission electron display.

3. Animals: SD rats, 6 weeks old, male, 180-220 g, clean grade, provided by the Experimental Animal Center of Henan Province.

4. Experimental grouping: Grouping: (1) Normal control group: 20 healthy SD rats, fed with triple distilled water on an empty stomach every morning, with a volume of 10ml/kg, for 8 consecutive weeks; (2) Alzheimer's rats Formula syndrome model group: 20 rat models of Alzheimer's syndrome were prepared by 2VO method; (3) the present invention group: 20 Alzheimer's syndrome model rats were fed with the solution of the present invention on an empty stomach every morning. The gastric concentration is 10mg/kg, and the volume of gavage is 10ml/kg, and the gavage is continued for 8 weeks;

5. Experimental content: Morphological observation under light microscope and electron microscope.

6. Results

6.1 Effect of the present invention on the morphology of cortical pyramidal cells in rat hippocampus CA1 area (light microscope 0.8K×). Three layers of pyramidal cells in hippocampal CA1 area of rats in Alzheimer's syndrome model group are arranged in disorder; some pyramidal cells are swollen, infiltrated with inflammatory cells, and astrocytes proliferate; some pyramidal cell bodies become smaller or triangular , the apical dendrites are elongated, with nuclear pyknosis and rupture, and the cytoplasm is uniformly eosinophilic; some pyramidal cells have shallower nuclei, loose matrix and microvacuole formation; erythrocytes exudate around blood vessels, and small blood vessels can be seen in individual cases hyperplasia. The high dose of the present invention group obviously inhibited the morphological changes of hippocampal CA1 pyramidal cells, and the cell morphology was basically normal, showing a typical three-layer cell arrangement.

As shown in Figure 3, Figure 3 is the impact of the present invention on the morphology of rat hippocampal CA1 cortical pyramidal cells (light microscope 0.8K ×) Alzheimer's syndrome model group hippocampal CA1 three-layer pyramidal cell arrangement disorder ; Some pyramidal cells are swollen, with inflammatory cell infiltration and astrogliosis; some pyramidal cells have smaller or triangular cell bodies, elongated apical dendrites, nuclear pyknosis and rupture, and uniform eosinophilic cytoplasm Red; the nuclei of some pyramidal cells become lighter, the matrix is loose with the formation of microvacuole; there is red blood cell exudation around the blood vessels, and small blood vessel proliferation can be seen in some cases. The group of the present invention can obviously inhibit the morphological changes of hippocampal CA1 pyramidal cells, and the cell morphology is basically normal, and a typical three-layer cell arrangement can be seen. The blank control group shown in Figure 3 is 1; the Alzheimer's syndrome model group is 2; and the invention group is 3.

6.2 Effect of the present invention on the morphology of cortical pyramidal cells in the CA1 region of the rat hippocampus (electron microscope 12K×). In the Alzheimer's syndrome model group, the pyramidal cells in the CA1 area of the hippocampus had pyknotic nuclei, chromatin aggregated into clusters and edge clusters, heterochromatin increased, and high electron density clusters could be seen around the nucleus; mitochondria swelled, and cristae fused and merged. Cavitation occurs. The group of the present invention can obviously inhibit damage to the nucleus and organelles of hippocampal CA1 pyramidal cells, and the morphology of the organelles is basically normal.

As shown in Figure 4, Figure 4 is the influence of the present invention on the morphology of cortical pyramidal cells in the CA1 region of the rat hippocampus (electron microscope 12K×). In the Alzheimer's syndrome model group, the pyramidal cells in the CA1 area of the hippocampus had condensed nuclei, chromatin aggregated into clusters, edge clusters, heterochromatin increased, and high electron density clusters could be seen around the nucleus; mitochondria swelled, and cristae fused and appeared Cavitation degeneration. The group of the present invention can obviously inhibit damage to the nucleus and organelles of hippocampal CA1 pyramidal cells, and the morphology of the organelles is basically normal. The blank control group shown in Figure 4 is 1; the Alzheimer's syndrome model group is 2; and the invention group is 3.

The form and characteristics of the pharmaceutically acceptable carrier or diluent described in the present invention are determined by the amount of active ingredient to be mixed with it, the route of administration, the process in vivo (including absorption, distribution, metabolism, excretion) and other known determined by the variable. These carriers must be "acceptable" in the sense that they should be compatible with the other ingredients of the formulation, not interfere with the efficacy of the formulation and not be deleterious to the recipients of the formulation. For example, the pharmaceutical carrier used can be solid or liquid. Examples of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, polyethylene glycol, polyvinylpyrrolidone, collagen hydrolyzate, and the like. Examples of liquid carriers are phosphate buffered saline, syrups, emulsions, wetting agents, sterile solutions and the like. Similarly, the carrier or diluent may include time delay materials well known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax. A wide range of drug forms are available. Thus, if a solid carrier is used, the preparation may be in the form of tablets, placed in powder or granules in hard gelatin capsules, troches or lozenges. The amount of solid carrier will vary widely but will preferably be from about 50 mg to about 1 g. When a liquid carrier is used, the preparation can be in the form of syrup, emulsion, soft gelatin capsule.

Claims (6)

1. a pharmaceutical composition that prevents Alzheimer formula syndrome, is characterized in that: it is formulated that this pharmaceutical composition comprises following raw materials according: friedelan 3 βol, resveratrol, astragalus polysaccharides component A1, astragalus polysaccharides component A2 and lycium barbarum polysaccharide component I.

2. the pharmaceutical composition of prevention Alzheimer formula syndrome according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 5～100 parts of friedelan 3 βols, 5～100 parts of resveratrols, astragalus polysaccharides component A110～100 part, 10～100 parts of astragalus polysaccharides component A210～100 part and lycium barbarum polysaccharide component I.

3. the pharmaceutical composition of prevention Alzheimer formula syndrome according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 5～80 parts of friedelan 3 βols, 5～80 parts of resveratrols, astragalus polysaccharides component A110～80 part, 10～80 parts of astragalus polysaccharides component A210～80 part and lycium barbarum polysaccharide component I.

4. the pharmaceutical composition of prevention Alzheimer formula syndrome according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 5～50 parts of friedelan 3 βols, 5～50 parts of resveratrols, astragalus polysaccharides component A110～50 part, 10～50 parts of astragalus polysaccharides component A210～50 part and lycium barbarum polysaccharide component I.

5. the pharmaceutical composition of prevention Alzheimer formula syndrome according to claim 1, it is characterized in that: it is formulated according to parts by weight that this pharmaceutical composition comprises following raw materials according: 5 parts of friedelan 3 βols, 5 parts of resveratrols, astragalus polysaccharides component A123 part, 19 parts of astragalus polysaccharides component A217 part and lycium barbarum polysaccharide component I.

6. the application of the pharmaceutical composition as described in claim 1-5 in the pharmaceutical composition of preparation prevention Alzheimer formula syndrome.

Images